Present and Future: Pharmacologic Treatment of Obesity

被引：39

作者：

Glandt, Mariela ^{[1
]}

Raz, Itamar ^{[2
]}

机构：

[1] Bronx Lebanon Hosp Ctr, Dept Endocrinol, Bronx, NY 10457 USA

[2] Univ Med Sch, Ctr Diabet, IL-12000 Jerusalem, Israel

来源：

JOURNAL OF OBESITY | 2011年 / 2011卷

关键词：

D O I：

10.1155/2011/636181

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Obesity now presents one of the biggest health problems of our times. Diet and exercise are best for both prevention and treatment; unfortunately, both require much discipline and are difficult to maintain. Medications offer a possible adjunct, but their effect is modest, they are limited by side effects, and the weight loss lasts only as long as the drug is being taken, since as soon as treatment is stopped, the weight is regained. Sibutramine, a sympathomimetic medication which was available for long-term treatment, is the most recent of the drugs to be withdrawn from the market due to side effects; in this case it was an increased risk of cardiovascular events. This paper reviews those medications which are available for treatment of obesity, including many of those recently taken off the market. It also discusses some of the newer treatments that are currently being investigated.

引用

页数：13

共 115 条

[31] Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice [J].

Douketis, JD ;

Macie, C ;

Thabane, L ;

Williamson, DF .

INTERNATIONAL JOURNAL OF OBESITY, 2005, 29 (10) :1153-1167

[32] Adaptive reduction in basal metabolic rate in response to food deprivation in humans: a role for feedback signals from fat stores [J].

Dulloo, AG ;

Jacquet, J .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 1998, 68 (03) :599-606

[33] The melanocortin melanocyte-stimulating hormone/adrenocorticotropin4-10 decreases body fat in humans [J].

Fehm, HL ;

Smolnik, R ;

Kern, W ;

McGregor, GP ;

Bickel, U ;

Born, J .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1144-1148

[34] CONTRASTING SHORT-TERM AND LONG-TERM EFFECTS OF WEIGHT-LOSS ON LIPOPROTEIN LEVELS [J].

FOLLICK, MJ ;

ABRAMS, DB ;

SMITH, TW ;

HENDERSON, LO ;

HERBERT, PN .

ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) :1571-1574

[35] The effect of metformin on the metabolic abnormalities associated with upper-body rat distribution [J].

Fontbonne, A ;

Charles, MA ;

JuhanVague, I ;

Bard, JM ;

Andre, P ;

Isnard, F ;

Cohen, JM ;

Grandmottet, P ;

Vague, P ;

Safar, ME ;

Eschwege, E .

DIABETES CARE, 1996, 19 (09) :920-926

[36] Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial [J].

Fontbonne, A. ;

Diouf, I. ;

Baccara-Dinet, M. ;

Eschwege, E. ;

Charles, M-A. .

DIABETES & METABOLISM, 2009, 35 (05) :385-391

[37] What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes [J].

Foster, GD ;

Wadden, TA ;

Vogt, RA ;

Brewer, G .

JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY, 1997, 65 (01) :79-85

[38] Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus [J].

Fujioka, K ;

Seaton, TB ;

Rowe, E ;

Jelinek, CA ;

Raskin, P ;

Lebovitz, HE ;

Weinstein, SP .

DIABETES OBESITY & METABOLISM, 2000, 2 (03) :175-187

[39] Zonisamide for weight loss in obese adults - A randomized controlled trial [J].

Gadde, KM ;

Franciscy, DM ;

Wagner, HR ;

Krishnan, KRR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (14) :1820-1825

[40] Are health care professionals advising obese patients to lose weight? [J].

Galuska, DA ;

Will, JC ;

Serdula, MK ;

Ford, ES .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (16) :1576-1578

← 1 2 3 4 5 6 7 8 9 10 →